{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:03:37Z","timestamp":1790751817591,"version":"4.1.0"},"reference-count":51,"publisher":"RCNi","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"DOI":"10.7748\/ns.2026.e12753","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:30:08Z","timestamp":1788251408000},"page":"59-65","source":"Crossref","is-referenced-by-count":0,"title":["Overview of weight loss medicines and practical advice for patients"],"prefix":"10.7748","volume":"41","author":[{"given":"Ruth Caroline","family":"Boocock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4499","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"key20260929140136_R1","article-title":"Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial","year":"2026","journal-title":"Nature Medicine"},{"issue":"1","key":"key20260929140136_R2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","year":"2024","journal-title":"JAMA"},{"key":"key20260929140136_R3","unstructured":"Byers R\n (2025) Written Evidence Submitted by Rebecca Byers at Novo Nordisk (FWM0152) \u2013 Health and Social Care Select Committee Inquiry: Food and Weight Management. committees.parliament.uk\/writtenevidence\/147774\/pdf (Last accessed: 28 July 2026.)"},{"issue":"4","key":"key20260929140136_R4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","year":"2019","journal-title":"Age and Ageing"},{"issue":"4","key":"key20260929140136_R5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archsurg.138.4.389","article-title":"Roles for ghrelin in the regulation of appetite and body weight","volume":"138","year":"2003","journal-title":"Archives of Surgery"},{"key":"key20260929140136_R6","unstructured":"Department of Health and Social Care (2026) UK Chief Medical Officers\u2019 Physical Activity Guidelines. www.gov.uk\/government\/publications\/physical-activity-guidelines-uk-chief-medical-officers-report\/uk-chief-medical-officers-physical-activity-guidelines (Last accessed: 28 July 2026.)"},{"issue":"1","key":"key20260929140136_R7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41387-025-00382-x","article-title":"Food noise: definition, measurement, and future research directions","volume":"15","year":"2025","journal-title":"Nutrition and Diabetes"},{"key":"key20260929140136_R8","article-title":"Nutritional, functional, and psychological considerations for incretin-based therapies in adults \u2013 An EASO, EFAD, and ECPO Consensus Statement","year":"2026","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"3","key":"key20260929140136_R9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000521241","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"15","year":"2022","journal-title":"Obesity Facts"},{"issue":"4","key":"key20260929140136_R10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","year":"2018","journal-title":"Cell Metabolism"},{"issue":"8","key":"key20260929140136_R11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","year":"2025","journal-title":"Nature Reviews Drug Discovery"},{"key":"key20260929140136_R12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3389\/fendo.2018.00443","article-title":"Dietary protein and energy balance in relation to obesity and co-morbidities","volume":"9","year":"2018","journal-title":"Frontiers in Endocrinology"},{"key":"key20260929140136_R13","unstructured":"Field S, Clarke J, Tallack C\n (2026) GLP-1 Drug Prescriptions for Obesity: Who Is Turning to Private Weight-Loss Treatment? www.health.org.uk\/reports-and-analysis\/analysis\/glp-1-drug-prescriptions-for-obesity (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R14","first-page":"73","volume-title":"Encyclopedia of Behavioral Medicine","year":"2020"},{"issue":"1","key":"key20260929140136_R15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12889-025-25876-2","article-title":"Public health policies and interventions to address health inequities in high-income countries: an umbrella review","volume":"26","year":"2026","journal-title":"BMC Public Health"},{"issue":"1","key":"key20260929140136_R16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s13679-025-00611-5","article-title":"The impact of novel medications for obesity on weight stigma and societal attitudes: a narrative review","volume":"14","year":"2025","journal-title":"Current Obesity Reports"},{"issue":"3","key":"key20260929140136_R17","doi-asserted-by":"crossref","first-page":"e12734","DOI":"10.1111\/cob.12734","article-title":"Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials","volume":"15","year":"2025","journal-title":"Clinical Obesity"},{"issue":"1","key":"key20260929140136_R18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-025-04528-7","article-title":"Prevalence of use and interest in using glucagon-like peptide-1 receptor agonists for weight loss: a population study in Great Britain","volume":"24","year":"2026","journal-title":"BMC Medicine"},{"issue":"1","key":"key20260929140136_R19","first-page":"1","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","year":"2024","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"key20260929140136_R20","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","year":"2024","journal-title":"eClinicalMedicine"},{"key":"key20260929140136_R21","author":"Joint Formulary Committee","year":"2026"},{"issue":"4","key":"key20260929140136_R22","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","year":"2022","journal-title":"British Journal of Pharmacology"},{"key":"key20260929140136_R23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","year":"2019","journal-title":"Frontiers in Endocrinology"},{"issue":"24","key":"key20260929140136_R24","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"key20260929140136_R25","unstructured":"Medicines and Healthcare products Regulatory Agency (2026a) GLP-1 Receptor Agonists and Dual GLP-1\/GIP Receptor Agonists: Strengthened Warnings on Acute Pancreatitis, Including Necrotising and Fatal Cases. www.gov.uk\/drug-safety-update\/glp-1-receptor-agonists-and-dual-glp-1-slash-gip-receptor-agonists-strengthened-warnings-on-acute-pancreatitis-including-necrotising-and-fatal-cases (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R26","unstructured":"Medicines and Healthcare products Regulatory Agency (2026b) GLP-1 Medicines for Weight Loss and Diabetes: What You Need to Know. www.gov.uk\/government\/publications\/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know\/glp-1-medicines-for-weight-loss-and-diabetes-what-you-need-to-know (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R27","unstructured":"Medicines and Healthcare products Regulatory Agency (2026c) First GLP-1 Tablet for Weight Loss Approved in the UK. www.gov.uk\/government\/news\/first-glp-1-tablet-for-weight-loss-approved-in-the-uk (Last accessed: 28 July 2026.)"},{"issue":"8","key":"key20260929140136_R28","first-page":"1475","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the","volume":"33","year":"2025","journal-title":"Obesity Medicine Association, and the Obesity Society. Obesity"},{"key":"key20260929140136_R29","volume-title":"Technology appraisal No. 664","author":"National Institute for Health and Care Excellence","year":"2020"},{"key":"key20260929140136_R30","volume-title":"Technology appraisal No. 875","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key20260929140136_R31","volume-title":"Technology appraisal No. 924","author":"National Institute for Health and Care Excellence","year":"2025"},{"key":"key20260929140136_R32","volume-title":"Technology appraisal No. 1026","author":"National Institute for Health and Care Excellence","year":"2025"},{"key":"key20260929140136_R33","volume-title":"NICE guideline No. 246","author":"National Institute for Health and Care Excellence","year":"2026"},{"key":"key20260929140136_R34","volume-title":"Technology appraisal No. 1152","author":"National Institute for Health and Care Excellence","year":"2026"},{"issue":"10531","key":"key20260929140136_R35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","year":"2026","journal-title":"Lancet"},{"key":"key20260929140136_R36","unstructured":"NHS England (2026) Interim Commissioning Guidance: Implementation of the National Institute for Health and Care Excellence (NICE) Technology Appraisal TA1026 and the NICE Funding Variation for Tirzepatide (Mounjaro\u00ae) for the Management of Obesity. www.england.nhs.uk\/long-read\/interim-commissioning-guidance-nice-ta1026-tirzepatide (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R37","unstructured":"Obesity Health Alliance (2023) Dietary and Health Inequalities: Obesity Health Alliance Position Statement. obesityhealthalliance.org.uk\/wp-content\/uploads\/2023\/02\/OHA-Health-Inequalities-Position-Statement-Final.pdf (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R38","unstructured":"Office for Health Improvement and Disparities (2025a) Obesity Profile: Short Statistical Commentary, May 2025. www.gov.uk\/government\/statistics\/obesity-profile-may-2025-update\/obesity-profile-short-statistical-commentary-may-2025 (Last accessed: 28 July 2026.)"},{"key":"key20260929140136_R39","unstructured":"Office for Health Improvement and Disparities (2025b) National Diet and Nutrition Survey 2019 to 2023: Report. www.gov.uk\/government\/statistics\/national-diet-and-nutrition-survey-2019-to-2023\/national-diet-and-nutrition-survey-2019-to-2023-report (Last accessed: 28 July 2026.)"},{"issue":"11","key":"key20260929140136_R40","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","year":"2024","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"key20260929140136_R41","doi-asserted-by":"crossref","first-page":"100186","DOI":"10.1016\/j.obpill.2025.100186","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","year":"2025","journal-title":"Obesity Pillars"},{"key":"key20260929140136_R42","first-page":"100228","article-title":"Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach","volume":"17","year":"2025","journal-title":"Obesity Pillars"},{"issue":"6","key":"key20260929140136_R43","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1111\/obr.70079","article-title":"Nutrition strategies for next-generation incretin therapies: a systematic scoping review of the current evidence","volume":"27","year":"2026","journal-title":"Obesity Reviews"},{"issue":"17","key":"key20260929140136_R44","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"key20260929140136_R45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/1468-0009.12498","article-title":"Is obesity policy in England fit for purpose? Analysis of government strategies and policies, 1992-2020","volume":"99","year":"2021","journal-title":"Milbank Quarterly"},{"issue":"14","key":"key20260929140136_R46","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"key20260929140136_R47","doi-asserted-by":"crossref","first-page":"e085304","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","year":"2026","journal-title":"BMJ"},{"issue":"1","key":"key20260929140136_R48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","year":"2022","journal-title":"Postgraduate Medicine"},{"issue":"8","key":"key20260929140136_R49","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","year":"2022","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"key20260929140136_R50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s42255-021-00383-x","article-title":"Postprandial glycaemic dips predict appetite and energy intake in healthy individuals","volume":"3","year":"2021","journal-title":"Nature Metabolism"},{"issue":"1","key":"key20260929140136_R51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"}],"container-title":["Nursing Standard"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.rcni.com\/doi\/pdf\/10.7748\/ns.2026.e12753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:40:46Z","timestamp":1790750446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.rcni.com\/doi\/10.7748\/ns.2026.e12753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9,30]]}},"alternative-id":["10.7748\/ns.2026.e12753"],"URL":"https:\/\/doi.org\/10.7748\/ns.2026.e12753","relation":{},"ISSN":["0029-6570","2047-9018"],"issn-type":[{"value":"0029-6570","type":"print"},{"value":"2047-9018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}